• WKN: A1EMG5
  • ISIN: DE000A1EMG56
  • Land: Deutschland

Nachricht vom 22.10.2021 | 19:18

SPORTTOTAL AG resolves to issue a convertible bond

SPORTTOTAL AG / Key word(s): Issue of Debt
SPORTTOTAL AG resolves to issue a convertible bond

22-Oct-2021 / 19:18 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Disclosure of insider information pursuant to Article 17 MAR

SPORTTOTAL AG resolves to issue a convertible bond

Cologne, 22 October 2021. The Management Board of SPORTTOTAL AG (the "Company") has today resolved, with the approval of the Supervisory Board, to issue a convertible bond from contingent capital.

The Management Board and the Supervisory Board of SPORTTOTAL AG have today resolved to issue a convertible bond of up to EUR 6,973,000.00 with a term to maturity of five years and an interest rate of 8.5 % p.a. ("Convertible Bond"). The Convertible Bond is divided up into up to 6,973 partial debentures, each of which confer entitlement to subscribe to 1,000 new shares in the Company after expiration of a waiting period. Shareholders' subscription rights were excluded by way of resolution passed by the Annual General Meeting of 26 May 2021. The partial debentures will be offered to qualified institutional investors for purchase in the context of a private placement. The Convertible Bond is expected to be subscribed in several tranches, with 1,000 partial debentures being subscribed in the first tranche.

Am Coloneum 2
50829 Cologne
Tel.: +49 (0)221_7 88 77_ 0
Fax: +49 (0)221_7 88 77_ 199


22-Oct-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at

show this

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

News im Fokus

Allianz SE: Allianz kündigt Abschluss eines Rückversicherungsvertrages in den USA an

03. Dezember 2021, 07:03

Aktueller Webcast

Deutsche Konsum REIT-AG

FY 2020/2021 Financial Results

16. Dezember 2021

Aktuelle Research-Studie

CEWE Stiftung & Co. KGaA

Original-Research: CEWE Stiftung & Co. KGaA (von GSC Research GmbH): Kaufen

02. Dezember 2021